Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Takeda Pharmaceuticals USA, Inc.
Inflammatory bowel disease (IBD) is a chronic, frequently
progressive condition that affects approximately 1.6 million people
in the United States. This lifelong, systemic autoimmune illness
often strikes patients at a young age and must be managed across a
lifetime. The diagnosis of IBD is most commonly based on imaging to
assess the portions of the small bowel that are inaccessible to
optical endoscopic visualization, which may also include a
combination of endoscopy and histopathology. Imaging plays a
critical role in the initial diagnosis and ongoing evaluation of IBD
patients. The treatment goal for IBD is to reduce the inflammation,
in hopes of achieving reduced symptoms and possibly remission.
Immediate goals are to control the symptoms, induction of remission,
and to help improve a patient’s quality of life, while long-term
goals include maintenance of a corticosteroid-free clinical
remission, mucosal healing, endoscopic remission, prevention or cure
of complications, restoration, and maintenance of proper nutrition.
The first step for IBD treatment is aminosalicylates, which are
useful for treating flares of IBD and for maintaining remission.
There are also the uses of antibiotics that treat bacterial
infections that may result from abscesses or fistulas.
Corticosteroids can be used and they are rapid-acting
anti-inflammatory agents and are indicated for acute flares of
disease only and have no role in the maintenance of remission.
Immunomodulators have a slower onset of action and work to reduce
patients’ overactive immune system but unlike corticosteroids, they
can be used as a long-term treatment. And the fifth way to treat IBD
is with biologics, which are proteins that stop certain molecules in
the body from causing inflammation in the GI tract. These are
usually prescribed to those living with moderate to severe cases of
IBD who haven’t responded to other types of treatment.
Upon completion of this
activity, participants will be able to:
Explore recent guidelines and
clinical trial data to inform the next generation of therapies
in inflammatory bowel disease (IBD)
Identify new diagnostic methods to
stratify patients with IBD to determine optimal customized
Analyze the safety and efficacy for
current and emerging treatments of IBD, including those with
specific therapeutic targets
Evaluate multidisciplinary care team
strategies to overcome different challenges in IBD management
Assess managed care considerations
that account for evolving therapeutic mechanisms in IBD
||Stephen B. Hanauer, MD
Professor of Medicine
serves as a consultant to AbbVie, Allergan, Amgen,
Arena, Boehringer Ingelheim, Bristol-Myers Squibb,
Celgene, Celltrion, Genentech, Gilead, GSK, Janssen,
Lilly, Merck, Pfizer, Prometheus, Receptos, Salix,
Samsung Bioepis, Seres Therapeutics, Takeda, and UCB
Pharma. He has received grant/research support (on
behalf of his institution) from AbbVie, Allergan, Amgen,
Celgene, Genentech, GKS, Janssen, Lilly, Pfizer,
Prometheus, Receptos, Takeda, and UCB. He serves on the
speaker’s bureau to AbbVie, Janssen, and Takeda. He has
served on the Data Safety Monitoring Board for Arena and
Bristol-Meyers Squibb. His presentation has been peer
reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by an
educational grant from
Takeda Pharmaceuticals USA, Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue